Keros Therapeutics, Inc.

Keros Therapeutics announced the resignation of Chief Financial Officer Keith Regnante, effective August 3, 2026, as he pursues other opportunities. Annita Tanini, the company's Corporate Controller and Vice President, Finance, has been appointed interim principal financial officer and principal accounting officer, effective August 4, 2026. Ms. Tanini will receive an annual base salary of $302,300 and is eligible for an annual cash bonus with a target of 30% of her base salary. The company has initiated a search for a permanent CFO.

Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026. The company highlighted Dr. Prener's extensive experience in clinical development and executive leadership, which is expected to be invaluable in advancing Keros' pipeline and corporate strategy. Dr. Prener expressed enthusiasm for joining Keros, citing its differentiated scientific approach and commitment to addressing unmet patient needs.

Keros Therapeutics, Inc. announced that its President and Chief Executive Officer, Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference. The event is scheduled for Monday, June 8, 2026, at 4:00 p.m. Eastern time, with a live audio webcast and an archived replay available for investors. Keros is a clinical-stage biopharmaceutical company developing novel therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins.

Keros Therapeutics reported a net loss of $(23.7) million for Q1 2026, a significant decline from a net income of $148.5 million in Q1 2025. Total revenue plummeted to $367 thousand from $211.2 million year-over-year, primarily due to the absence of large license revenue recognized in the prior year. The company's cash and cash equivalents stood at $281.5 million as of March 31, 2026, down from $287.4 million at the end of 2025. Management believes existing cash will allow operations for at least the next 12 months, but continued viability depends on raising additional capital.

Keros Therapeutics reported a net loss of $23.7 million for Q1 2026, a significant decrease from a net income of $148.5 million in Q1 2025, primarily due to lower revenue from a Takeda license agreement and reduced R&D expenses. The company's partner, Takeda, plans to advance elritercept into a Phase 3 clinical trial for anemia in myelofibrosis. Keros maintains a strong cash position of $281.5 million, expected to fund operations into the first half of 2028.